| Stuart Demirs, MD | |
|
4099 Old Post Rd, Charlestown, RI 02813 | |
| (401) 364-0770 | |
| (401) 364-7694 |
| Full Name | Stuart Demirs |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 36 Years |
| Location | 4099 Old Post Rd, Charlestown, Rhode Island |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285685560 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | MD08161 (Rhode Island) | Secondary |
| 207R00000X | Internal Medicine | MD08161 (Rhode Island) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| South County Home Health | Narragansett, RI | Home health agency |
| South County Hospital Inc | Wakefield, RI | Hospital |
| Westerly Hospital | Westerly, RI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Stuart V Demirs Md Llc | 9739410408 | 2 |
News Archive
more than 50 million worldwideA new study in the journal Nature has reported the pathology of blindness caused by age-related macular degeneration or AMD. This condition affects more than 50 million worldwide and is incurable. The researchers report that when an enzyme known as DICER1 stops functioning AMD starts to develop.
Bristol-Myers Squibb Company and Pfizer today announced that the companies have agreed to stop the Phase 3 AVERROES clinical trial of apixaban in patients with atrial fibrillation. The study will be stopped early because a predefined interim analysis by the independent Data Monitoring Committee (DMC) revealed clear evidence of a clinically important reduction in stroke and systemic embolism in patients with atrial fibrillation considered intolerant of or unsuitable for vitamin K antagonist therapy who received apixaban as compared to aspirin.
Rural/Metro Corporation, a leading provider of ambulance and private fire protection services, today is launching a tender offer and consent solicitation for its outstanding 9.875% Senior Subordinated Notes due 2015 (the "Notes").
Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary a tentative approval for its Abbreviated New Drug Application (ANDA) to market a generic version of IPR Pharmaceutical's Crestor ® tablets 5 mg, 10 mg, 20 mg, 40 mg.
› Verified 4 days ago
| Entity Name | Stuart V Demirs Md Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417515354 PECOS PAC ID: 9739410408 Enrollment ID: O20191010000555 |
News Archive
more than 50 million worldwideA new study in the journal Nature has reported the pathology of blindness caused by age-related macular degeneration or AMD. This condition affects more than 50 million worldwide and is incurable. The researchers report that when an enzyme known as DICER1 stops functioning AMD starts to develop.
Bristol-Myers Squibb Company and Pfizer today announced that the companies have agreed to stop the Phase 3 AVERROES clinical trial of apixaban in patients with atrial fibrillation. The study will be stopped early because a predefined interim analysis by the independent Data Monitoring Committee (DMC) revealed clear evidence of a clinically important reduction in stroke and systemic embolism in patients with atrial fibrillation considered intolerant of or unsuitable for vitamin K antagonist therapy who received apixaban as compared to aspirin.
Rural/Metro Corporation, a leading provider of ambulance and private fire protection services, today is launching a tender offer and consent solicitation for its outstanding 9.875% Senior Subordinated Notes due 2015 (the "Notes").
Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary a tentative approval for its Abbreviated New Drug Application (ANDA) to market a generic version of IPR Pharmaceutical's Crestor ® tablets 5 mg, 10 mg, 20 mg, 40 mg.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Stuart Demirs, MD Po Box 910, Charlestown, RI 02813-0901 Ph: (401) 364-0770 | Stuart Demirs, MD 4099 Old Post Rd, Charlestown, RI 02813 Ph: (401) 364-0770 |
News Archive
more than 50 million worldwideA new study in the journal Nature has reported the pathology of blindness caused by age-related macular degeneration or AMD. This condition affects more than 50 million worldwide and is incurable. The researchers report that when an enzyme known as DICER1 stops functioning AMD starts to develop.
Bristol-Myers Squibb Company and Pfizer today announced that the companies have agreed to stop the Phase 3 AVERROES clinical trial of apixaban in patients with atrial fibrillation. The study will be stopped early because a predefined interim analysis by the independent Data Monitoring Committee (DMC) revealed clear evidence of a clinically important reduction in stroke and systemic embolism in patients with atrial fibrillation considered intolerant of or unsuitable for vitamin K antagonist therapy who received apixaban as compared to aspirin.
Rural/Metro Corporation, a leading provider of ambulance and private fire protection services, today is launching a tender offer and consent solicitation for its outstanding 9.875% Senior Subordinated Notes due 2015 (the "Notes").
Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary a tentative approval for its Abbreviated New Drug Application (ANDA) to market a generic version of IPR Pharmaceutical's Crestor ® tablets 5 mg, 10 mg, 20 mg, 40 mg.
› Verified 4 days ago